Posts

Showing posts with the label GLP-1

Being Fitter May Help Your Kidneys Age More Slowly, New Study Finds

Image
Your fitness level today could be a clue to how well your kidneys age. A new study from Japan has found that adults with higher cardiorespiratory fitness experienced a slower decline in kidney function over five years — suggesting that staying fit may help protect the kidneys long before any disease appears. The research, published in the November 2026 issue of Medicine & Science in Sports & Exercise, followed 198 adults with healthy kidney function, with a median age of 61.4 years. The team from the University of Tsukuba, led by Shun Yoshikoshi, measured each participant's cardiorespiratory fitness — the body's ability to supply oxygen during sustained activity — using a submaximal cycling test, then tracked their kidney function annually for five years. The results were clear: participants with higher fitness showed a slower decline in kidney function when it was estimated using cystatin C, a blood marker of how efficiently the kidneys filter waste. The link held even...

Orangetheory to Train All 6,500 Coaches for the GLP-1 Era in First-of-Its-Kind Fitness Partnership

Image
  Orangetheory Fitness is making a major bet on the future of weight loss: the popular workout chain announced on Monday, November 16, that it will train its entire global coaching network to support members taking GLP-1 medications. The company says it is the first fitness brand to partner with the National Academy of Sports Medicine (NASM) to train all of its more than 6,500 coaches worldwide. Every coach will complete NASM's "Understanding Weight Loss Medications" course, with systemwide completion targeted for February 2027. The training is designed to help coaches understand how GLP-1 and GIP medications work, their common side effects, and how to support members through exercise and lifestyle coaching. Coaches will not prescribe or manage medications — those decisions remain with each member's health care provider — and they will not ask members whether they are taking a GLP-1 drug. For members, the change comes with no separate class, sign-up or added cost. Coa...

Stopping Ozempic and Other GLP-1 Drugs May Double Heart Attack and Stroke Risk, Major Study Finds

Image
  People with type 2 diabetes who stop taking GLP-1 weight-loss and diabetes drugs such as Ozempic face nearly double the risk of a heart attack, stroke or death compared with those who stay on treatment, according to a major new study. The research, published in The Lancet Regional Health – Europe, analysed electronic medical records from more than 80,000 people with type 2 diabetes and no established heart disease, treated at 301 diabetes clinics across Italy between 2004 and 2024. The findings are striking. People who discontinued their GLP-1 treatment had about twice the combined risk of a non-fatal heart attack, a non-fatal stroke or death from any cause compared with those who continued — 3.94 events per 100 person-years versus 1.96. Death from any cause alone was around 4.8 times higher among those who stopped, at 2.23 versus 0.48 deaths per 100 person-years. More than six in ten of the patients in the study — 48,615 of 80,302 — had stopped their GLP-1 treatment by their las...

FDA Orders New Eye Warning on Ozempic, Wegovy and All GLP-1 Drugs Over Rare Vision Risk

Image
The U.S. Food and Drug Administration has ordered a new safety warning on every GLP-1 weight-loss and diabetes drug sold in the United States, after identifying a potential increased risk of a rare eye condition that can cause sudden vision loss. In a Drug Safety Communication issued on November 9, 2026, the FDA said it is requiring manufacturers of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to add information about non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their product labels. NAION, often described as an "eye stroke," is caused by reduced blood flow to the optic nerve. It can cause sudden, painless vision loss in one eye, including blind spots, tunnel vision or distorted colours, and the damage is usually not reversible. The warning covers the full GLP-1 class, including Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Saxenda and Victoza (liraglutide), and Trulicity...

Popular posts from this blog

Eating Less Protein Could Slow Aging, Major Review of 350 Studies Suggests

Build Muscle, Beat Diabetes: Why Strength Training Is a Powerful Tool for Blood Sugar Control This World Diabetes Day

Your Waist Size May Matter More Than Your Weight, Massive Study of 17 Million Adults Finds